FDA Seeks Comments on Medical Device Paperwork
Published Date: 7/6/2026
Notice
Summary
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 2 costs, 1 mixed.
Big Increase in PMA Paperwork Burden
If you are a Premarket Approval (PMA) applicant or holder of Class III medical devices, the FDA estimates total annual reporting burden of 1,182,316 hours and recordkeeping burden of 29,240 hours. The agency says this represents an overall reporting increase of about 244% and a recordkeeping increase of about 212% compared with prior estimates.
New Pediatric and Clinical Trial Reporting
FDA is adding burden for reporting pediatric-use information under section 515A and for certifications under 42 U.S.C. 282(j)(5)(B) using Form FDA 3674. The estimate in the notice shows pediatric-related reporting at 8,306 total hours annually and Form FDA 3674 certification at 46 total hours annually.
Shift to eSTAR Electronic Submissions
FDA is promoting eSTAR electronic submission templates and expects them to reduce submission burden, but also estimates initial eSTAR setup effort. The notice lists eSTAR setup at a total of 734 hours annually and describes eSTAR as a tool to 'significantly reduce burden' by providing a uniform electronic format.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
2026-13492 — Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has confirmed that vasopressin in sodium chloride (0.9%, injection) wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can now get approved if they meet all the rules, helping patients and healthcare providers get more options. No changes in price or availability are expected right now, but more generics could be coming soon!
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13346 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Products
The FDA is updating how it collects info about Medication Guides—those important leaflets that come with some prescription drugs to keep patients safe. This affects drug makers who must follow new rules about what info to include and how to share it. Comments on these changes are open until July 31, 2026, and the update aims to keep patients informed without adding extra costs.
Previous / Next Documents
Previous: 2026-13518 — Prohibiting Importation and Marketing of Previously Authorized Covered Communications Equipment Added to the Covered List in 2024 or Earlier
Starting July 16, 2026, the FCC is banning the import and sale of certain communications gear that was once allowed but now poses security risks. This affects companies dealing with equipment added to the risky list in 2024 or earlier, stopping them from bringing in or marketing these products. The move helps protect U.S. safety without canceling past approvals, but it means businesses must adjust quickly to avoid losses.
Next: 2026-13520 — Self-Regulatory Organizations; MIAX PEARL, LLC; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change by To Amend the By-Laws To Establish the Role of Observers
MIAX PEARL is updating its rules to create a new role called Observers on its Board. These Observers will have specific rights and a clear nomination process. The changes also clean up old rules about Equity Rights Programs, and they take effect right away, impacting how the company’s leadership works but not your wallet.